William Ackman
Bill Ackman runs hedge fund Pershing Square Capital, which he started in 2003 following the dissolution of Gotham Partners.
Ackman is a value investor with an activist bent. Activist investors agitate management for changes. He owns large positions in Target (NYSE: TGT) and Borders (NYSE: BGP). He has also been involved in activist situations at Wendy's (NYSE: WEN) and McDonald's (NYSE: MCD).
Ackman proved his acumen as a short seller in 2007/2008 as short positions he held in MBIA (NYSE: MBI) and Ambac (NYSE: ABK) proved to be big winners due to the credit crunch.
In July 2008, Ackman said he was short the common stock of Fannie Mae (NYSE: FNM) and Freddie Mac (NYSE: FRE). Ackman also laid out a plan to reorganize the GSEs, which would wipe out the common shareholders.
View Older Stories View More Recent Stories
-
Bill Ackman expects 'very significant' Valeant Pharma (VRX) assets sales by year-end
-
Ackman Feels 'Sad' for Michael Pearson on Forced Valeant (VRX) Sale
-
Valeant Pharma (VRX) call volume and volatility up into CNBC appearance by Ackman
-
Bill Ackman Will Be on CNBC's Halftime Report Today (VRX) (HLF)
-
Have Valeant Pharma (VRX) Shareholders Finally Capitulated?
-
S&P Removes Pershing Square from CreditWatch Negative as Valeant (VRX) Stabilizes
-
Ackman releases new Herbalife video; stock climbs
-
Ackman's Pershing Square Updates on Valeant Pharma (VRX) Options Position
-
Valeant's former CEO to receive $9 million severance payment, other fees
-
Valeant Pharma (VRX) Rejected Joint Takeda, TPG Takeover Approach - WSJ
-
Activist investor heavyweights form new lobbying arm
-
Ackman's Pershing Square's 13F Shows Increased Stake in Restaurant Brands (QSR), Valeant (VRX), Lowered Stake in Air Products (APD), Mondelez (MDLZ), More ...
-
Following Perrigo's (PRGO) Q1 Results, Some Question Valeant's (VRX) New CEO Pick
-
Key player in Pershing Square's Valeant bet leaving firm
-
Ackman's Pershing Square seeks to sell Zoetis shares for $800 million: NYT
-
Bill Ackman to Sell $800M in Zoetis (ZTS) Stock - NYT
-
Valeant Pharma (VRX) may change its name at some point - Bill Ackman
-
Ackman defends Valeant, hints at more changes
-
Valeant Pharma (VRX) has no plans to sell 'crown jewel' assets - Bill Ackman
-
Bill Ackman regrets investing in Valeant Pharma (VRX)
-
Valeant Pharma (VRX) is not a 'sewer' - Ackman
-
Ackman compares Valeant Pharma (VRX) investment now to Warren Buffett's investment in Goldman Sachs (GS) in 2009
-
Valeant Pharma (VRX) Sharply Lower, But on Watch Ahead of Ackman CNBC Interview
-
Warren Buffett Comments on Valeant Pharma (VRX)
-
Valeant annual report reveals new issues, company overhauls board
-
Valeant to name four new directors as soon as Friday: WSJ
-
Bill Ackman says that he expects Valeant Pharma (VRX) to file its 10k by Friday
-
Ackman, Valeant pledge reforms after spiking drug prices
-
Bill Ackman, Pearson, Schiller Among Valeant's (VRX) Senate Hearing Wtnesses
-
Valeant names Papa CEO after he resigns from Perrigo
-
Valeant in talks to hire Perrigo's Papa as CEO: source
-
Exclusive: Valeant calls in investment banks to weigh options - sources
-
Legg Mason's Miller Thinks Valeant (VRX) Stock Could Double, Has Been Buying Shares
-
S&P Downgrades Valeant Pharma (VRX) to 'B'; Notes Escalation in Near-Term Default Risk
-
Wall St. ends higher but indexes post weekly losses
-
Ackman Shoots Down Idea of Valeant (VRX) Unloading Bausch & Lomb
-
Valeant gets extra month to file annual report
-
Valeant Pharma (VRX) Ramps to Session Highs
-
Pershing Square's Ackman Says Valeant (VRX) was Passive Holding Until Recent, Board Focused on CEO Search
-
Ackman to face investor grilling after record quarterly loss
-
Ackman's fund falls 7 percent in March, hurt by Valeant
-
Regulator orders drugmaker Valeant management to cease trading
-
Ackman's Amends Valeant Pharma (VRX) 13D to Add Director Consent for MCTO
-
Valeant CEO subpoenaed to testify before U.S. Senate panel
-
Senate's request for info from Ackman related to Valeant: source
-
Ackman Sees Confidence Restored in Valeant Pharma (VRX) After 10-K Filed, New Leadership Identified
-
Ackman Skipping Sohn Investment Conference to Focus on Valeant (VRX)
-
Valeant Pharma (VRX) Gains as Ackman Gets Hands On
-
Valeant (VRX) is Not Investable - Piper Jaffray
-
Valean (VRX) Changes Seen as Steps in the Right Direction - BMO Capital

